In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.03 below Bioxytran Inc average.

Within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Bioxytran Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3887, from total ranking in the first quarter 2026 at 4395.

Explain Quick Ratio?
How much Cash & cash equivalents BIXT�s has?
What are BIXT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BIXT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	89.55 %	46.36 %	23.79 %	146.13 %	126.52 %
Y / Y Cash & cash equivalent Change	5541.98 %	10549.66 %	9793.56 %	-58.18 %	-76.75 %
Quick Ratio MRQ	0.03	0.09	0.16	0	0
BIXT's Total Ranking	# 3887	# 4395	# 5316	# 5505	# 5545
Seq. Current Liabilities Change	5.28 %	59.18 %	2.83 %	9.99 %	-18.71 %
Seq. Cash & cash equivalent Change	-61.69 %	-9.19 %	3416.89 %	361.16 %	-27.69 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 885
Overall Market	# 4160

Quick Ratio Statistics
High	Average	Low
1.19	0.1	0
(Jun 30 2011)		(Sep 30 2020)

Financial Statements
Bioxytran Inc 's Current Liabilities	$ 5 Millions	Visit BIXT's Balance sheet
Bioxytran Inc 's Cash & cash equivalent	$ 0 Millions	Visit BIXT's Balance sheet
Source of BIXT's Sales		Visit BIXT's Sales by Geography

Cumulative Bioxytran Inc 's Quick Ratio

BIXT's Quick Ratio for the trailling 12 Months

BIXT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	65.06 %	65.94 %	102.5 %	72.85 %	26.14 %
Y / Y Cash & cash equivalent TTM Growth	2361.74 %	1616.94 %	739.34 %	-67.8 %	-63.57 %
Quick Ratio TTM	0.07	0.07	0.04	0	0
Total Ranking TTM	# 3462	# 4223	# 3650	# 3672	# 3680
Seq. Current Liabilities TTM Growth	17.8 %	12.78 %	5.12 %	18.19 %	18.42 %
Seq. Cash & cash equivalent TTM Growth	17.59 %	86.24 %	1859.5 %	-42.63 %	-17.99 %

Quick ratio ranking by company, industry and sector >> Back to BIXT Financial Strength Comparisons >> Go to Compare BIXT Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q2 2026 to $5.27 millions, cumulative Quick Ratio remained unchanged at 0.07 above the BIXT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Bioxytran Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3242.

Explain Quick Ratio?
How much Cash & cash equivalents BIXT�s has?
What are BIXT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 912
Within the Market	# 3887

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.27	0.06	0
(Jun 30 2012)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Galectin Therapeutics Inc	0.09	$ 13.275 Millions	$ 151.619 Millions
Lftd Partners Inc	0.08	$ 0.304 Millions	$ 3.648 Millions
Processa Pharmaceuticals Inc	0.08	$ 0.196 Millions	$ 2.387 Millions
Cv Sciences Inc	0.05	$ 0.266 Millions	$ 4.943 Millions
Citius Pharmaceuticals Inc	0.05	$ 17.008 Millions	$ 333.952 Millions
Sunshine Biopharma Inc	0.05	$ 0.281 Millions	$ 5.619 Millions
Hcw Biologics Inc	0.04	$ 0.741 Millions	$ 18.648 Millions
China Pharma Holdings Inc	0.04	$ 0.305 Millions	$ 7.682 Millions
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions
Cdt Equity Inc	0.03	$ 0.700 Millions	$ 23.351 Millions
Shuttle Pharmaceuticals Holdings Inc	0.03	$ 0.102 Millions	$ 3.481 Millions
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions
Os Therapies Incorporated	0.01	$ 0.205 Millions	$ 20.653 Millions
The Greater Cannabis Company Inc	0.01	$ 0.000 Millions	$ 0.012 Millions
Chemocentryx Inc.	0.01	$ 1.253 Millions	$ 139.868 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.003 Millions	$ 0.341 Millions
Evofem Biosciences Inc	0.01	$ 0.714 Millions	$ 88.615 Millions

Date modified: 2026-09-26T07:07:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.